- Home
- KYTX vs CGEN Comparison
KYTX vs CGEN Comparison
Compare KYTX & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KYTX
- CGEN
- Stock Information
- Founded
- KYTX 2018
- CGEN 1993
- Country
- KYTX United States
- CGEN Israel
- Employees
- KYTX N/A
- CGEN N/A
- Industry
- KYTX
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KYTX
- CGEN Health Care
- Exchange
- KYTX NYSE
- CGEN Nasdaq
- Market Cap
- KYTX 125.2M
- CGEN 149.6M
- IPO Year
- KYTX 2024
- CGEN 2000
- Fundamental
- Price
- KYTX $1.93
- CGEN $1.46
- Analyst Decision
- KYTX Buy
- CGEN Strong Buy
- Analyst Count
- KYTX 4
- CGEN 1
- Target Price
- KYTX $19.00
- CGEN $4.00
- AVG Volume (30 Days)
- KYTX 294.1K
- CGEN 286.0K
- Earning Date
- KYTX 03-27-2025
- CGEN 03-04-2025
- Dividend Yield
- KYTX N/A
- CGEN N/A
- EPS Growth
- KYTX N/A
- CGEN N/A
- EPS
- KYTX N/A
- CGEN N/A
- Revenue
- KYTX N/A
- CGEN $27,864,000.00
- Revenue This Year
- KYTX N/A
- CGEN $22.94
- Revenue Next Year
- KYTX N/A
- CGEN $15.88
- P/E Ratio
- KYTX N/A
- CGEN N/A
- Revenue Growth
- KYTX N/A
- CGEN N/A
- 52 Week Low
- KYTX $1.90
- CGEN $1.35
- 52 Week High
- KYTX $25.84
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- KYTX 27.74
- CGEN 32.02
- Support Level
- KYTX $2.20
- CGEN $1.50
- Resistance Level
- KYTX $2.57
- CGEN $1.65
- Average True Range (ATR)
- KYTX 0.19
- CGEN 0.07
- MACD
- KYTX -0.02
- CGEN 0.00
- Stochastic Oscillator
- KYTX 4.00
- CGEN 12.50
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.